Halozyme Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.03.14	Halozyme: European Approval Of Roche's MabThera SC For Non-Hodgkin Lymphoma (RTTNews)
26.03.14	ACT Gets It Right, CPRX On The Move, HALO Shines, Keep Watch On GALT, INSM (RTTNews)
25.03.14	Halozyme's HTI-501 Meets Primary Endpoint In Phase 1/2 Clinical Trial (RTTNews)
27.02.14	Halozyme Therapeutics Q4 Loss Widens (RTTNews)
05.02.14	Halozyme Prices Offering Of 7.69 Mln Shares At $13.00 Per Share (RTTNews)
17.12.13	Halozyme Therapeutics Names Helen Torley CEO (RTTNews)
02.12.13	Baxter Submits Amended Biologics License Application For HyQvia To FDA (RTTNews)
08.11.13	Halozyme Therapeutics Q3 Loss Narrows (RTTNews)
22.10.13	SWOG Initiates Randomized Phase 2 Clinical Trial of Halozyme's PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer (PR Newswire)
21.10.13	Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros (PR Newswire)
15.10.13	Yale Researchers Initiate Clinical Trial Evaluating Halozyme's Recombinant Hyaluronidase in Artificial Pancreas Study (PR Newswire)
11.10.13	Technical Study: Gilead Sciences Inc., NPS Pharmaceuticals Inc., Halozyme Therapeutics Inc., and InterMune Inc. (PR Newswire)
10.10.13	Stock Option Grants, FDA Agreements, Financing Transactions, Clinical Trial Updates, and New Appointments - Research Report on Aegerion, CTI, PDL, Halozyme, and Acorda (PR Newswire)
01.10.13	Merger Updates, Milestone Payments, AGM Results, Review of Strategic Alternatives and Other Corporate Announcements - Research Report on Cubist, Halozyme, Taro, Galena and Sequenom (PR Newswire)
30.09.13	Halozyme Presents PEGPH20 Phase 1b Results At European Cancer Congress 2013 (RTTNews)
30.09.13	Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013 (PR Newswire)
26.09.13	Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche (PR Newswire)
20.09.13	Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference (PR Newswire)
12.09.13	Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc. (PR Newswire)
12.09.13	Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress (PR Newswire)
03.09.13	CYTK To Take A Hit, Tune Into ESPR, Watch Out For HALO Effect (RTTNews)
02.09.13	Halozyme: Roche Gets EU Marketing Approval For Breast Cancer Drug Herceptin SC (RTTNews)
02.09.13	Halozyme: Breast Cancer Drug Herceptin SC Gets Marketing Authorization In EU (RTTNews)
12.08.13	Public Offerings of Common Stock, Financial Results, and Significant Progress in Key Development Programs - Research Report on BioCryst, Exelixis, Idenix, Puma Biotechnology, and Halozyme (PR Newswire)
07.08.13	Halozyme Reports Second Quarter 2013 Financial Results (PR Newswire)
06.08.13	Early Briefing and Review: Gilead Sciences, InterMune, NPS Pharma, and Halozyme Therapeutics (PR Newswire)
01.08.13	Pre-market Movers For Aug 1 (XOM, PG, COP, CI, DTV, DELL, JCP, YELP, CTRP, HALO) (RTTNews)
01.08.13	Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20 (PR Newswire)
07.11.09	Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme (Businesswire)
22.10.09	Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin® (Businesswire)
07.08.09	Halozyme Therapeutics Reports Second Quarter 2009 Financial Results (Businesswire)
27.07.09	Halozyme Therapeutics Appoints Jonathan Leff, M.D. as Vice President, Chief Medical Officer (Businesswire)
23.06.09	Halozyme Therapeutics Raises $40 Million in Public Offering of Common Stock (Businesswire)
17.06.09	Halozyme Therapeutics Appoints Herceptin® Pioneer, H. Michael Shepard, Ph.D., as Vice President of Discovery Research (Businesswire)
06.06.09	Halozyme’s Phase 2 Insulin-PH20 Study Demonstrates Faster Insulin Absorption and Superior Glucose Control in Type 1 Diabetic Patients (Businesswire)
13.04.09	Halozyme Therapeutics Names New Chief Financial Officer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Halozyme Therapeutics Inc.

Aktien Top/Flop

Meistgelesene Nachrichten